Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Compstatins: the dawn of clinical C3-targeted complement inhibition

Trends in Pharmacological Sciences(2022)10.1016/j.tips.2022.01.004Source: DataRank Database

Compstatins: the dawn of clinical C3-targeted complement inhibition is a research paper published in Trends in Pharmacological Sciences (2022). On theSindex it has a DataRank of 0. It has been cited 71 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access71 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (15 grants)OA: greenTopics (22)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Dimitrios C. Mastellos ORCID,Daniel Ricklin ORCID,John D. Lambris ORCID,Christina Lamers ORCID

Live enrichment

PubMed:35090732 PMC:PMC9553322

National Institutes of Health

Grant: AI030040

National Institutes of Health

Grant: AI068730

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Grant: 31003A_176104

NIAID NIH HHS

Grant: R01 AI030040

NIAID NIH HHS

Grant: N01 AI030040

NIAID NIH HHS

Grant: P01 AI068730

Swiss National Science Foundation

Grant: 176104

Therapeutic Modulation of Adverse Host Defense System Activation on Biomaterial and Cell Surfaces

Shire

Grant: unidentified

unidentified

National Institutes of Health

Grant: N01AI030040-002

BACTERIAL RESPIRATORY PATHOGENS RESEARCH UNIT-

Alexion Pharmaceuticals

Shire

Sanofi

Baxter International

Viropharma

Roche

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/9553322

publisherhttps://api.elsevier.com/content/article/PII:S0165614722000050?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0165614722000050?httpAccept=text/plain

https://doi.org/10.1016/j.tips.2022.01.004

https://pubmed.ncbi.nlm.nih.gov/35090732

Fields of Study

0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

HumansHemoglobinuria, ParoxysmalHemolysisPeptides, CyclicComplement System ProteinsComplement C3Antibodies, Monoclonal, Humanized

Keywords

Complement systemCompstatinParoxysmal Nocturnal Hemoglobinuria (Pnh)PegcetacoplanC3 InhibitorHemoglobinuria, ParoxysmalHumansComplement C3Complement System ProteinsAntibodies, Monoclonal, HumanizedHemolysisPeptides, Cyclic

Sustainable Development Goals

SDG 3: 3. Good health